Articles On Zelda Therapeutics (ASX:ZLD)

For a while there, it seemed like the Australian cannabis sector had stalled. Not only were many cannabis companies in limbo thanks to a large backlog of licensing applications, but all the exciting mergers and acquisitions in the industry...

Strong gains among selected life science shares is fuelling optimism the sector may have further to run. Life sciences stocks are involved in things like biotech, genetics, pharmaceuticals and medical devices. In a low growth earnings envir...

Current Zelda Therapeutics (ASX:ZLD) boss Dr Richard Hopkins cut an animated figure at a media briefing for his company’s proposed merger with US-based Ilera Therapeutics last week. And while the market hasn’t exactly followed suit — shares...

Two and a half years ago, cannabis was so hot Stemcell United (ASX:SCU) went from 1 cent to 19 cents in one day. The catalyst was the appointment of a cannabis expert to look for opportunities. “Now people want revenues and a genuine busine...

The merger will bring together a leading pipeline of clinical candidates, revenue-generating medicines, and a combined strategy to disrupt global medicinal cannabis and pharmaceutical markets.

Zelda Therapeutics Ltd, Zelda Therapeutics news, Zelda Therapeutics share price, Zelda Therapeutics Proactive, Zelda Therapeutics Hot Copper, Zelda Therapeutics executive chairman and co-founder Harry Karelis and managing director Dr Richar...

Cannabis company Zelda Therapeutics Ltd (ASX: ZLD) has seen its share price push higher today after it announced a major development. Its shares were up as much as 7.5% to 8.6 cents in morning trade before dropping back a touch. What did Z...

Major Australian medical cannabis group Zelda Therapeutics (ASX: ZLD) has announced a landmark merger with America's Ilera Therapeutics. While the companies have been partners in manufacturing and distributing cannabis products for some t...

Medicinal cannabis company Zelda Therapeutics has announced a "merger of equals" with privately-held US-based counterpart Ilera Therapeutics.  

On Stockhead today: five water treatment stocks surge 260 per cent in a year, the ASX’s most intriguing bargain barrel stocks, the five 2019 IPO stocks delivering triple returns and Dorado-3 oil flow gets Carnarvon on track. But first:   Th...

The company’s securities will remain in a trading halt until the beginning of trade on October 10 or when an announcement is released.

Kicking back at your favourite cafe and smoking a joint is an activity historically associated with pot-friendly cities such as Amsterdam. But as of this week, that right has now been extended to US citizens with the grand opening of Americ...

You may have heard about an opioid crisis over in the US; it was declared a public health emergency in 2017 amid 130 deaths every day from opioid-related drug overdoses and 2.1 million people with an opioid use disorder. In Australia, the p...

Drugs intake in the form of pills, capsules, and tablets are not the most efficient ways of taking medicine, because only about 25% of the drug reaches where it should. Several factors including food affect, enzymatic degradation, drug meta...

Cannabis was once synonymous with drugs, marijuana, ill-health and the scourges of our society. Presently, cannabis is associated with medication, business and legalisation. This proves that we have come a long way in the cannabis space, an...

With growing focus of governments across the globe on legalising recreational and medicinal cannabis, the cannabis industry is booming at a rapid pace and is expected to offer opportunities for investors. In 2016, Australia became the fourt...

‘Pot stocks’ were making headlines in 2018. California, one of the world’s biggest economies and the most populous state in the US, finally enacted legislation to legalise the recreational use of cannabis. It joined a growing list of US st...

Parents of more than 100 kids aged about 10 are reporting how the treatments affect the children’s behaviour.

SUDA Pharmaceuticals Ltd (ASX: SUD) is transforming the drug delivery technology to improve the lifestyle and health of the global community by offering innovative and high-quality oro-mucosal spray pharmaceutical products to aid in the tre...

The healthcare industry of Australia is a key contributor in developing the economy. The companies who are in this industry, have to update them with the new medicine for the treatment of the diseases. The healthcare space of Australia is p...

To increase the bioavailability of administered medications, Australian-headquartered SUDA Pharmaceuticals Ltd (ASX: SUD) is reformulating medications into an oral spray. The delivery of medications through the oral mucosa increases the amo...

Australia has established its strong position in the contemporary world that is welcoming the good side of cannabis with open arms, amid the recreational legalising debates. The country joined the bandwagon of Alaska, Canada, North Korea an...

The federal government has taken steps to cut red tape and speed up the granting of licences for Australia’s cannabis players. Health Minister Greg Hunt said the federal government would boost the nation’s medicinal cannabis industry by pri...

Zelda Therapeutics Ltd (ASX: ZLD) Cannabis Group Zelda Therapeutics released its quarterly results for the three months ended 30 June 2019. The company reported a continued progress in its core clinical and preclinical programs and is in th...

Today, we hear from Maxim Jacobs, managing partner at New York-based Edison Investment Research.   What’s hot? Jacobs told Stockhead the hottest sector “by far” is cannabis. “While some people may consider it to be a bubble there is a subst...

An oro-mucosal drug delivery company headquartered in Perth, SUDA Pharmaceuticals Ltd (ASX: SUD) uses its OroMist® technology for the development of low-risk oral sprays. The company reformulates the existing pharmaceuticals into an oral sp...

A new chain of medical cannabis clinics are set to roll out across Australia as part of a collaboration between Australian biopharma Zelda Therapeutics (ASX:ZLD) and Emerald Clinics. Zelda is developing a new cannabis-based treatment to red...

Zelda Therapeutics (ASX:ZLD) has entered a strategic collaboration with Australian-based Emerald Clinics to access clinical data from patients treated with medicinal cannabis for pain and insomnia.

Stem cell manufacturer Cynata Therapeutics (ASX: CYP) has announced this morning it has received an acquisition proposal. Japanese pharmaceutical company Sumitomo Dainippon Pharma has proposed to acquire the company for $2 per share (which...

The agreement supports Zelda’s path to rapid commercialisation through the development of clinically validated cannabis medicines.

The Australian bio-pharmaceutical company is developing proprietary cannabinoid formulations to treat a variety of medical conditions.

As the cannabis sector gains momentum in Australia and given that medicinal cannabis was legalised in February 2016, at a federal level, various companies are rapidly advancing their clinical trials for relevant products to capitalise on th...

Californian cannabis company Caliva has signed on billionaire rapper Shawn “Jay-Z” Carter to promote its brand as the drug becomes legal recreationally in more states. Caliva said Jay-Z, as the company’s chief brand strategist, would “play...

Wth the legalisation of medical cannabis in many countries like Canada, the global medical cannabis industry has boomed quite a bit in recent times. Let’s take a quick look at 20 cannabis companies trading on ASX. Cann Group Limited (ASX:...

The cannabis market is expected to grow multi-fold in the next decade, given the legalisation of Cannabis around the world for its medicinal properties and recreational purposes. Three important pot stocks are Zelda Therapeutics Limited, Cr...

The ASX’s 32 tradeable pot stocks and pot stock wannabees are down 17 per cent over the last 12 months. The Small Ords (ASX:XSO) has risen 1.62 per cent in the same time, and the All Ords (ASX:XAO) and the ASX200 (ASX:XJO) are both up over...

Do you know that market enthusiasts believe that legalising cannabis would generate approximately $8.5 billion in the country’s federal and state tax? Ponder over the massive revenue that this sector would add to the necessities related to...

Zelda Therapeutics (ASX:ZLD) is no stranger to testing for positive health effects derived from medicinal cannabis products. In its latest step, the company has obtained approval to test for the viability of medical marijuana in the treatme...

The phase I trial will begin immediately with preliminary results expected later this quarter and full results in quarter four of 2019.

Bio-pharmaceutical company Zelda Therapeutics (ASX: ZLD) has taken a decisive step towards mitigating the effects of the growing opioid epidemic that is gripping several Western countries including Australia and the US. Earlier today, Zelda...

Zelda Therapeutics (ASX:ZLD) has announced that its phase 1 Opioid Reduction Trial has been formally approved by the St Vincent’s Hospital Ethics and Governance Committees.

One of Australia's leading cannabis companies Zelda Therapeutics (ASX: ZLD) has been given the greenlight to commence an opioid reduction trial. The trial at St Vincent's Hospital in Melbourne will see Zelda assess the effectiveness of me...

Australian cinephiles have two silver screen shows made just for the cannabis crowd to watch. Feature-length film ‘High as Mike’ traces one Tamworth man’s difficult undertaking to access medical cannabis to treat his brain cancer. And the...

The company’s medicinal cannabis products are aimed at treating pain, anxiety, sleep apnea and cancer.